These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 19995151)

  • 1. Tibolone reduces osteoporotic fracture risk and breast cancer risk, but increases the risk of stroke.
    de Melo NR; Pompei LM
    Gynecol Endocrinol; 2010 Feb; 26(2):73-5. PubMed ID: 19995151
    [No Abstract]   [Full Text] [Related]  

  • 2. Tibolone: the way to beat many a postmenopausal ailments.
    Lazovic G; Radivojevic U; Marinkovic J
    Expert Opin Pharmacother; 2008 Apr; 9(6):1039-47. PubMed ID: 18377345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tibolone revisited: still a good treatment option for healthy, early postmenopausal women.
    Kenemans P
    Gynecol Endocrinol; 2010 Apr; 26(4):237-9. PubMed ID: 20017707
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer.
    Dimitrakakis C; Keramopoulos D; Vourli G; Gaki V; Bredakis N; Keramopoulos A
    Climacteric; 2005 Dec; 8(4):342-51. PubMed ID: 16390769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Is the clinical profile of women treated with tibolone similar to that of women receiving a classical estrogen-progestogen therapy? Data from a nationwide survey in France].
    Jamin C; Bourg F; Legeai J; Senoussi S
    Gynecol Obstet Fertil; 2006 Mar; 34(3):224-32. PubMed ID: 16513401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tibolone and breast cancer risk: effects of selection bias cannot be eliminated in observational studies.
    Coomarasamy A
    BJOG; 2008 Jun; 115(7):919. PubMed ID: 18485174
    [No Abstract]   [Full Text] [Related]  

  • 7. By the way, doctor. What happened to tibolone--the estrogen alternative we heard about a while ago? Did it turn out not to be effective?
    Robb-Nicholson C
    Harv Womens Health Watch; 2004 Apr; 11(8):8. PubMed ID: 15100062
    [No Abstract]   [Full Text] [Related]  

  • 8. What have we really learned from 'LIBERATE' trial?
    Dimitrakakis C; Tsigginou A; Keramopoulos D; Antsaklis A
    Maturitas; 2010 May; 66(1):99-100. PubMed ID: 20236777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of tibolone in older postmenopausal women.
    Cummings SR; Ettinger B; Delmas PD; Kenemans P; Stathopoulos V; Verweij P; Mol-Arts M; Kloosterboer L; Mosca L; Christiansen C; Bilezikian J; Kerzberg EM; Johnson S; Zanchetta J; Grobbee DE; Seifert W; Eastell R;
    N Engl J Med; 2008 Aug; 359(7):697-708. PubMed ID: 18703472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose tibolone (1.25 mg/d) does not affect muscle strength in older women.
    Ribom EL; Svensson P; van Os S; Larsson M; Naessen T
    Menopause; 2011 Feb; 18(2):194-7. PubMed ID: 20689464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hormone therapy and risk for breast cancer in Finnish postmenopausal women].
    Lyytinen H; Ylikorkala O
    Duodecim; 2011; 127(3):235-42. PubMed ID: 21438346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The LIBERATE tibolone trial in breast cancer survivors.
    Speroff L
    Maturitas; 2009 May; 63(1):1-3. PubMed ID: 19327923
    [No Abstract]   [Full Text] [Related]  

  • 13. Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials.
    Biglia N; Maffei S; Lello S; Nappi RE
    Gynecol Endocrinol; 2010 Nov; 26(11):804-14. PubMed ID: 20586550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of tibolone on the breast of postmenopausal women.
    Wang PH; Cheng MH; Chao HT; Chao KC
    Taiwan J Obstet Gynecol; 2007 Jun; 46(2):121-6. PubMed ID: 17638619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormone replacement therapy use and variations in the risk of breast cancer.
    Opatrny L; Dell'Aniello S; Assouline S; Suissa S
    BJOG; 2008 Jan; 115(2):169-75; discussion 175. PubMed ID: 18081598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular effects of tibolone: a selective tissue estrogenic activity regulator.
    Campisi R; Marengo FD
    Cardiovasc Drug Rev; 2007; 25(2):132-45. PubMed ID: 17614936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tibolone and breast cancer.
    Prescrire Int; 2010 Dec; 19(111):281. PubMed ID: 21355381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of hormone replacement with tibolone on plasma insulin and blood glucose in postmenopause].
    Saucedo RP; Basurto L; Fonseca E; Zárate A
    Ginecol Obstet Mex; 2001 Aug; 69():301-3. PubMed ID: 11599314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Postmenopausal hormonal treatment: conventional hormone replacement therapy or tibolone? Effects on bone].
    Reginster JY
    J Gynecol Obstet Biol Reprod (Paris); 2002 Oct; 31(6):541-9. PubMed ID: 12407324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of oestrone sulphatase activity by tibolone and its metabolites.
    Purohit A; Malini B; Hooymans C; Newman SP
    Horm Metab Res; 2002 Jan; 34(1):1-6. PubMed ID: 11832993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.